Citation

85 FR 49387

Canonical document for this Federal Register citation.

Prospective Grant of an Exclusive Start-Up Patent License for Evaluation: Immunotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma Thursday, August 13, 2020 85 FR 49387